Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "Ranchi"

123 News Found

Domestic growth to the fore as US weakness persists: ICICI Direct
News | October 19, 2021

Domestic growth to the fore as US weakness persists: ICICI Direct

ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report


Alcon announces launch of AcrySof IQ Vivity in India,
Medical Device | October 19, 2021

Alcon announces launch of AcrySof IQ Vivity in India,

It is the first presbyopia-correcting lens implant for cataract surgery


Global Health files DRHP for over Rs 500 crore issue
News | October 01, 2021

Global Health files DRHP for over Rs 500 crore issue

Global Health operates a network of four hospitals under the Medanta brand in Gurugram, Indore, Ranchi and Lucknow. In addition, one hospital is under construction in Patna, and another is planned for development in Noida


MedleyMed enters the U.S. market with a suite of digital health solutions
Digitisation | September 26, 2021

MedleyMed enters the U.S. market with a suite of digital health solutions

The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021


Jharkhand to set up pharma park
Policy | September 15, 2021

Jharkhand to set up pharma park

The pharma park will be built at an estimated cost of Rs 34.94 crore and will be spread over 50 acres at Chanho close to Ranchi


Novartis secures new approval in China for Cosentyx in pediatric psoriasis
Drug Approval | August 18, 2021

Novartis secures new approval in China for Cosentyx in pediatric psoriasis

Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch


Aster DM Heathcare plans India expansion
Healthcare | August 16, 2021

Aster DM Heathcare plans India expansion

Investment of Rs 235 crores to add 411 beds in the next 18 months


QIAGEN receives U.S. FDA emergency use authorization to analyze over 30 samples per hour
Digitisation | August 10, 2021

QIAGEN receives U.S. FDA emergency use authorization to analyze over 30 samples per hour

QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes


Cipla posts  net profit at Rs 715 crores
News | August 08, 2021

Cipla posts net profit at Rs 715 crores

India business contributes to a stellar performance


Poxel and Sumitomo Dainippon gets TWYMEEG approval
News | June 25, 2021

Poxel and Sumitomo Dainippon gets TWYMEEG approval

The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies